Skip to main content
. 2020 Aug 14;7:515. doi: 10.3389/fvets.2020.00515

Table 6.

Descriptive analysis and univariable logistic regression results for risk factors for polyuria and/or polydipsia within 31 days after receiving systemic glucocorticoid therapy among dogs under primary veterinary care in the UK.

Variable Category Case No. (%) Non-case No. (%) Odds ratio 95% CI Category P-value Variable P-value
Purebred status Crossbred 17 (24.29) 656 (22.45) Base 0.719
Purebred 53 (75.71) 2266 (77.55) 0.9 0.52–1.57 0.716
Common breeds Crossbreed 17 (23.94) 593 (20.25) Base 0.39
Boxer 4 (5.63) 61 (2.08) 2.29 0.75–7.01 0.148
Bichon 3 (4.23) 67 (2.29) 1.56 0.45–5.47 0.486
Labrador Retriever 8 (11.27) 179 (6.11) 1.56 0.66–3.67 0.31
German Shepherd Dog 3 (4.23) 71 (2.42) 1.47 0.42–5.15 0.544
Lhasa Apso 2 (2.82) 59 (2.01) 1.18 0.27–5.24 0.825
Border Collie 2 (2.82) 62 (2.12) 1.13 0.25–4.98 0.877
Cavalier King Charles Spaniel 0 68 (2.32) Empty
Cocker Spaniel 3 (4.23) 111 (3.79) 0.94 0.27–3.27 0.926
West Highland White Terrier 4 (5.63) 171 (5.84 0.82 0.27–2.46 0.718
Shih Tzu 2 (2.82) 97 (3.31) 0.72 0.16–3.16 0.663
Yorkshire Terrier 2 (2.82) 105 (3.58) 0.66 0.15–2.92 0.588
Staffordshire Bull Terrier 3 (4.23) 230 (7.85) 0.45 0.13–1.57 0.212
Jack Russell Terrier 1 (1.41) 178 (6.08) 0.20 0.03–1.48 0.114
Other purebred 17 (23.94) 877 (29.94) 0.68 0.34–1.34 0.26
Sex Female 31 (43.66) 1295 (44.21) Base 0.918
Male 40 (56.34) 1630 (55.65) 1.03 0.64–1.65 0.918
Age (years)a ≤2.0 5 (7.04) 713 (24.47) Base <0.001
2.0– ≤ 5.0 20 (28.17) 808 (27.73) 3.53 1.32–9.45 0.012
5.0– ≤ 8.0 17 (23.94) 615 (21.11) 3.94 1.45–10.75 0.007
>8.0 29 (40.85) 778 (26.70) 5.32 2.05–13.81 0.001
Bodyweight (kg)b ≤10.0 12 (16.90) 810 (27.65) Base 0.319
>10.0–20 17 (23.94) 739 (25.23) 1.55 0.74–3.27 0.247
>20.0–30 13 (18.31) 429 (14.65) 2.05 0.93–4.52 0.077
>30.0–40 9 (12.68) 266 (9.08) 2.28 0.95–5.48 0.064
>40 5 (7.04) 134 (4.57) 2.52 0.87–7.26 0.087
Not recorded 15 (21.13) 551 (18.81) 1.84 0.85–3.96 0.120
Route of systemic glucocorticoid administration (within 31 days) Injectable 10 (14.08) 1,353 (46.19) Base <0.001
Oral 42 (59.15) 1,349 (46.06) 4.21 2.10–8.43 <0.001
Both oral and injectable 19 (26.76) 227 (7.75) 11.32 5.20–24.67 <0.001
Active systemic glucocorticoid substance (Within 31 days) Injectable: Dexamethasone Sodium Phosphate 7 (9.86) 805 (27.48) Base <0.001
Injectable: Dexamethasone Phenylpropionate, Dexamethasone Sodium Phosphate 2 (2.82) 457 (15.60) 0.5 0.10–2.43 0.393
Other injectable only 2 (2.82) 92 (3.14) 2.5 0.51–12.21 0.258
Oral: Methylprednisolone 0 120 (4.10) Empty
Oral: Prednisolone 44 (61.97) 1,233 (42.10) 4.1 1.84–9.16 <0.001
Oral: Prednisolone- and injectable Dexamethasone Sodium Phosphate 13 (18.31) 184 (6.28) 8.12 3.20–20.65 <0.001
Other oral and injectable combinations 3 (4.23) 38 (1.30) 9.08 2.26–36.49 <0.001
Season Winter 14 (19.72) 621 (21.20) Base 0.075
Spring 24 (33.80) 609 (20.79) 1.75 0.9–3.41 0.102
Autumn 17 (23.94) 780 (26.63) 0.97 0.47–1.98 0.926
Summer 16 (22.54) 919 (31.38) 0.77 0.37–1.59 0.484
Neuter status Entire 13 (18.31) 981 (33.49) 0.018
Neutered 50 (70.42) 1,671 (57.05) 2.26 1.22–4.18 0.009
Unrecorded 8 (11.27) 277 (9.46) 2.18 0.89–5.31 0.087
a

Age at having a side effect for cases and age at a random treatment for non-cases.

b

Within 31 days of treatment for dogs <18 month and any body weight in 2013 for adults.